Your browser doesn't support javascript.
loading
A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.
Ryang, Soree; Kim, Sang Soo; Bae, Ji Cheol; Han, Ji Min; Kwon, Su Kyoung; Kim, Young Il; Nam-Goong, Il Seong; Kim, Eun Sook; Kim, Mi-Kyung; Lee, Chang Won; Yoo, Soyeon; Koh, Gwanpyo; Kwon, Min Jeong; Park, Jeong Hyun; Kim, In Joo.
Affiliation
  • Ryang S; Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea.
  • Kim SS; Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.
  • Bae JC; Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea.
  • Han JM; Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.
  • Kwon SK; Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
  • Kim YI; Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
  • Nam-Goong IS; Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, South Korea.
  • Kim ES; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
  • Kim MK; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
  • Lee CW; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
  • Yoo S; Department of Internal Medicine, Inje University Haeundae Paik Hospital, College of Medicine, Inje University, Busan, South Korea.
  • Koh G; Department of Internal Medicine, Busan St. Mary's Hospital, Busan, South Korea.
  • Kwon MJ; Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, South Korea.
  • Park JH; Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, South Korea.
  • Kim IJ; Division of Endocrinology & Metabolism, Department of Internal Medicine, Busan Paik Hospital, College of Medicine, Inje University, Busan, South Korea.
Diabetes Obes Metab ; 24(9): 1800-1809, 2022 09.
Article in En | MEDLINE | ID: mdl-35581902
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / Metformin Type of study: Clinical_trials Limits: Humans Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2022 Type: Article Affiliation country: South Korea
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / Metformin Type of study: Clinical_trials Limits: Humans Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2022 Type: Article Affiliation country: South Korea